Scribd
Upload
117 views2 pages

Doze IECA - Sartani

This document compares the equivalent doses of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) based on clinical trials. It provides tables listing the approximate dose equivalencies between common ARBs and ACEIs used to lower blood pressure. Considerations for changing between an ARB and ACEI like monitoring renal function and blood pressure are also mentioned. References supporting the dose comparisons are provided.

Uploaded by

Alexandra
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
117 views2 pages

Doze IECA - Sartani

This document compares the equivalent doses of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) based on clinical trials. It provides tables listing the approximate dose equivalencies between common ARBs and ACEIs used to lower blood pressure. Considerations for changing between an ARB and ACEI like monitoring renal function and blood pressure are also mentioned. References supporting the dose comparisons are provided.

Uploaded by

Alexandra
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

THE DOSE

An estimation of equivalent doses between ARBs and ACEIs

ARBs still currently available as of Jan 26, 2020:


 Twynsta (telmisartan/amlodipine): 40/5mg. 40/10mg, 80/5mg, 80mg/ 10mg Note: ~$0.73/tablet (ODB covered)
 Candesartan/Hydrochlorothiazide:16mg/12.5mg, 32mg/12.5mg, 32mg/25mg
 Irbesartan/Hydrochlorothiazide: 150/12.5mg, 300/12.5mg, 300/25mg
 Olmesartan/Hydrochlorothiaizde: 20/12.5mg, 40/12.5mg
 Valsartan/Hydrochlorothiazide: 80/12.5mg, 160/12.5mg, 160/25mg, 320/12.5mg, 320/25mg
Note: Availability changes daily. Some pharmacies are able to get candesartan (4mg, 8mg, and 32mg) and irbesartan (300mg).

Considerations
 Patients renal function and hepatic function should be taken into consideration
 Patients should have blood pressure, lytes and SCr checked with rotation from ARB to ACEI as clinically indicated in 1-4
weeks
 ACEIs can cause a dry cough in 5-35% of patients and carry a risk of angioedema (0.1-0.2%)

Comparable dosages between ACEIs and ARBs- Summary of trials


Lisinopril 20mg Enalapril 20mg Perindopril 4mg Ramipril 10mg
Candesartan 16mg 8mg 16mg
Irbesartan 150mg
Telmisartan 80mg 40-80mg 40mg ~80mg
Valsartan 160mg 80mg
Note: There are variations for approximate equivalent dosages between ACEIs and ARBs in clinical trials.

Approximate equivalent doses of ACEI for blood pressure lowering


Drug Approximate Initial Daily Dose Usual Daily Maintenance Dose Maximum Daily Duration of
Dose Dose Action
Equivalence
Between ACEIs
Cilazapril 2.5mg 2.5-5mg 2.5-5mg dailya 10mg 12-24 hr
Enalapril maleate 5mg 2.5-5mg 10-40mg daily (or divided bid)a 40mg 12-24 hr
Fosinopril 10mg 10mg 10-40mg daily (or divided bid)a 40mg 24hr
Lisinopril 10mg 2.5-10mg 10-40mg daily 80mg 24hr
Perindopril 2mg 2-4mg 4-8mg daily 8mg 24hr
Quinapril 10mg 5-10mg 10-20mg dailya 40mg 24hr
Ramipril 2.5mg 1.25mg-2.5mg 2.5-10mg daily (or divided bid)a 20mg ~24hr

a: Some patients may experience a diminished antihypertensive effect toward the end of a 24-hour dosing interval. Splitting the daily dose into 2
equal 12-hourly doses or increasing the once-daily dose may be considered.

Approximate equivalent doses of ARBS for blood pressure lowering


Drug Approximate Dose Equivalence Initial Dose Usual Maintenance Maximum Daily Dose
Between ARBs Dose
Candesartan 8mg 8mg daily 8-32mg daily 32mg
Irbesartan 150mg 75mg daily 150-300mg daily 300mg
Losartan 50mg 25mg daily 50-100mg daily 100mg
Olmesartan 20mg 20mg daily 20-40mg daily 40mg
Telmisartan 40mg 40mg daily 40-80mg daily 80mg
Valsartan 80mg 80mg daily 80-320mg daily 320mg

For further information contact your primary care pharmacist

Thames Valley Family Health Team Drug Resource D. Angevine RPh. Jan. 2020
References:

 Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement EVERESTE study. Journal
of Human Hypertension 2002 16, 865-873
 The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical
trials. Blood pressure monitoring 2007, 12:141-147
 A Multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory
blood pressure monitoring. AM J Hypertens 2006;19:104-112
 The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood
pressure monitoring (PRISMA 1) Journal of hypertension 2006, 24:193-200
 Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;
351:1952-61
 Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan a selective AT 1 receptor antagonist, compared with
enalapril in elderly patients with primary hypertension. TEES study group. J Hypertens 1999; 17:293-302
 Mogensen CE, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with
hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria
(CALM) study. BMJ 2000;321:1440-1444.
 Derosa G, Cicero AF, Ciccarelli et al. A randomized, double-blind,controlled, parallel-group comparison of perindopril and
candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther. 2003 Jul;25(7):2006-2
 Pierre Larochelle, John M. Flack, Thomas C. Marbury, Pinhas Sareli, Eduardo M. Krieger, Richard A. Reeves et al. Effects and
Tolerability of Irbesartan Versus Enalapril in Patients With Severe Hypertension, Princeton, New Jersey., The American
Journal of Cardiology, Volume 80, Issue 12, 1997, Pages 1613-1615,
 Zanchetti A, Omoni S, Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study
Group. Am J Hypertens 2001 Feb; 14(2):129-34
 Holwerda NJ et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and
safety compared with placebo and enalapril. J Hypertens 1996 Sep; 14 (9):1147-51
 Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy
or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of
Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004 Jun; 26: 855–65
 Modernized Reference Drug Program. Angiotensin Converting Enzyme Inhibitors (ACEIs) Retrieved from
https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/rdp_decisiontree_aceis.pdf. Accessed Jan
24, 2020.
 Modernized Reference Drug Program. Angiotensin Receptor Blockers (ARBs)
https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/rdp_decisiontree_arbs.pdf. Accessed Jan 24,
2020.
 CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2016 [updated 2019 Feb; cited 2020 Jan 24]. Angiotensin-
Converting Enzyme (ACE) Inhibitors [product monograph]. Available from: http://www.e-cps.ca or http://www.myrxtx.ca.
Also available in paper copy from the publisher.

Thames Valley Family Health Team Drug Resource D. Angevine RPh. Jan. 2020

You might also like